Huons Global cleared for clinical trials for botulinum toxin in China

South Korea’s beauty and healthcare product maker Huons Global received a go-ahead from China for an investigational new drug (IND) application for its independently developed botulinum toxin (BTX).

The company announced Monday that China’s National Medical Products Administration (NMPA) approved the IND application for Hutox on April 30. It will confirm the efficacy of the treatment in improving moderate to severe forehead wrinkles by conducting phase 3 clinical trials by next year.

“The approval from China would accelerate our entry into the Chinese market,” said Huons Global CEO Kim Wan-sup. “We will work hard to conduct the clinical trials without any problems to make sure the product’s successful release in the market.”

[ⓒ Maeil Business Newspaper & mk.co.kr, All rights reserved]